Boston BioCom is a biomedical technology commercialization company created to earn a superior return for its investors by actively developing and managing a hand-picked portfolio of biomedical innovations towards optimal commercial endpoints.
The company brings together preeminent academic expertise, industry-leading pharmaceutical capabilities, and a highly experienced management team to create value from an extraordinary flow of technology opportunities.
Background
The Boston BioCom business model originated in 2003 when the U.S. Department of State engaged a team from the Center for the Integration of Medicine and Innovative Technology (CIMIT) - a consortium of Harvard Medical School, Massachusetts Institute of Technology and other Boston institutes - to canvass the Russian biomedical research community and identify technologies from selected institutions that...
Read MoreTechnology
Our Company has access to an impressive pipeline of technology opportunities originating from the Partners HealthCare research network as well as from a large number of Russian research institutions. To date Boston BioCom has initiated development of three specific programs. A fourth program, in central nervous system disease therapy, is under development.
Read MorePress Releases
Boston BioCom’s work selected for presentation at the Dana Farber Cancer Center Research Symposium on Breast and Ovarian Cancer.
Boston, MA, May 5, 2010